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Abstract
Background: In the setting of an acute stroke, anemia has the potential to worsen brain ischemia, however, the
relationship between the entire range of hemoglobin to long-term outcome is not well understood.
Methods: We examined the association between World Health Organization-defined admission anemia status
(hemoglobin<13 in males, <12 g/dl in women) and hemoglobin concentration and 1-year outcome among 859
consecutive patients with acute stroke (ischemic or intracerebral hemorrhage).
Results: The mean baseline hemoglobin concentration was 13.8 ± 1.7 g/dl (range 8.1 - 18.7). WHO-defined anemia
was present in 19% of patients among both women and men. After adjustment for differences in baseline
characteristics, patients with admission anemia had an adjusted OR for all-cause death at 1-month of 1.90 (95% CI,
1.05 to 3.43) and at 1-year of 1.72 (95% CI, 1.00 to 2.93) and for the combined end-point of disability, nursing
facility care or death of 2.09 (95% CI, 1.13 to 3.84) and 1.83 (95% CI, 1.02 to 3.27) respectively. The relationship
between hemoglobin quartiles and all-cause death revealed a non-linear association with increased risk at
extremes of both low and high concentrations. In logistic regression models developed to estimate the linear and
quadratic relation between hemoglobin and outcomes of interest, each unit increment in hemoglobin squared
was associated with increased adjusted odds of all-cause death [at 1-month 1.06 (1.01 to 1.12; p = 0.03); at 1-year
1.09 (1.04 to 1.15; p < 0.01)], confirming that extremes of both low and high levels of hemoglobin were associated
with increased mortality.
Conclusions: WHO-defined anemia was common in both men and women among patients with acute stroke and
predicted poor outcome. Moreover, the association between admission hemoglobin and mortality was not linear;
risk for death increased at both extremes of hemoglobin.
Background
Low hemoglobin, or anemia is a common condition
among older adults, with prevalence increasing with age.
Anemia is associated with increased mortality [1-4], dis-
ability, and poorer physical performance [5] regardless
of the underlying cause of the low hemoglobin. In
patients with acute coronary syndromes as well as in
patients with angina, anemia is an independent indicator
of short and long-term mortality [6-8]. At the other end
of the range of hemoglobin, patients with an acute cor-
onary syndrome or congestive heart failure with high
hemoglobin values also exhibit excess mortality, suggest-
ing a non-linear reverse J-shaped relationship [8,9].
Among community dwelling elderly, findings are incon-
sistent but some have observed a similar relationship
with mortality [1,3] as well as with a lower level of cog-
nitive function [10].
The relationship between the entire range of hemoglo-
bin and outcome after stroke is not well understood.
G i v e nt h er e l e v a n c eo fh e m o g l o b i nt oo x y g e nc a r r y i n g
capacity, inflammatory processes, oxidative stress, as
well as to blood viscocity and cerebral blood flow, we
hypothesized that extremes of both low and high hemo-
globin are associated also with poor outcome in the set-
ting of an acute stroke. Our aims were, therefore, to
evaluate in a large cohort of patients hospitalized for an
acute stroke: a. the predictive value of admission anemia
status; b. the association between the entire range of
hemoglobin concentration and stroke outcome.
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A prospective cohort study was conducted on 883 con-
secutive patients hospitalized due to acute stroke in a
large medical center with a catchment area of about
500,000 people from March 2001 to June 2002. Baseline
hemoglobin was missing in 24 patients, thus the final
study cohort included 859 patients. Patients were evalu-
ated systematically for risk factors, stroke severity, type
and subtype. Risk factors were assessed from medical
records and self-report. Severity of stroke was assessed
using the National Institutes of Health Stroke Scale
(NIHSS) [11]. Intracerebral hemorrhage and ischemic
stroke were differentiated by the results of the baseline
head CT scan. Ischemic stroke etiology was determined
by the TOAST classification, a system for categorization
of subtypes of ischemic stroke mainly based on etiology
that has been developed for the Trial of Org 10172 in
Acute Stroke Treatment [12]. A clinical evaluation and
personal interview was performed after 1-months and a
phone follow-up interview after 1-year, after obtaining
informed consent. The study was approved by the local
Institutional Review Board.
Laboratory methods
Hemoglobin was measured with the Beckman Coulter
MAXM/HMX analyzer (Beckman Coulter, Miami, FL)
using the manufacturer’s reagents and methods. The
first hemoglobin measurement performed at hospital
admission served as the index hemoglobin. Anemia was
defined by the World Health Organization (WHO) cri-
teria as a hemoglobin concentration <12 g/dl in women
and <13 g/dl in men. Chronic kidney disease was
defined according to the National Kidney Foundation
and American Heart Association with a glomerular fil-
tration rate < 60 mL/min/1.73 m
2,e s t i m a t e db yt h e4
variables modification of diet in renal disease equation
[13], from baseline serum creatinine measured at a cen-
tral laboratory using the Jaffe assay.
Outcomes of interest
Outcomes were assessed during the first year after the
stroke. During hospitalization and at 1-month follow-up,
data were collected by clinical evaluation and personal
interviews with patients and/or proxies. One-year after
the stroke, phone follow-up interviews were conducted
by professional interviewers from the Israeli Center for
Disease Control blinded to in-hospital data. Functional
outcome were assessed using the Barthel Index [14] with
a score <75 regarded as dependent in daily activities.
Mortality data were derived from the Israeli Population
Registry. The main outcome of interest was all-cause
death. In addition, the combined end-point of disability,
nursing facility care or all-cause death was assessed.
Statistical analyses
Anemia was analyzed according to the WHO criteria
and hemoglobin concentrations by gender-specific quar-
tiles: First, <12.3 in women, <13.3 in men; second, 12.3-
13.1 in women, 13.3-14.2 in men; third, 13.2-14.1
in women, 14.3-15.2 in men; forth, ≥ 14.2 in women,
≥ 15.3 g/dl in men. Unadjusted event rates for end-
points of interest by anemia status and gender-specific
quartiles were compared using c
2 test. To examine the
relationship between anemia status and outcomes of
interest, logistic regression models were conducted. The
shape of the relationship between hemoglobin and event
rates for end-points of interest was examined by plotting
gender-specific hemoglobin quartiles against the percen-
tage of each end-point. The plots showed a quadratic
relationship. Then, logistic regression models were
developed to estimate the linear and quadratic relation
between hemoglobin and outcomes of interest. The vari-
able hemoglobin was centered on its respective mean.
All models were adjusted for age, gender, stroke type,
stroke severity (NIHSS), prior disability, chronic kidney
disease, other cardiac disease and malignancy. To deter-
mine whether the relationship of hemoglobin to mortal-
ity was influenced by gender, we repeated the adjusted
regression models by adding the interaction of each
hemoglobin term with gender. To visualize the relation
between hemoglobin and all-cause death as demon-
strated in the final logistic regression model the Loess
method was used. The Loess method is a locally
weighted scatterplot smoothing that helps determining
the shape of the function that best summarizes the scat-
ter plot between 2 continuous variables [15]. The
method requires the input of a “smoothing parameter,”
which is the fraction of the data that are used around
each point. An algorithm for choosing an optimal value
for the smoothing parameter according to objective cri-
teria, described by Hurvich and Simonoff [16], was used.
For 1 year survival Cox proportional hazard model was
used to calculate adjusted HR. All analyses were per-
formed with SAS statistical software version 8.2 (SAS,
Inc, Cary, NC).
Results
The characteristics of the 859 study patients are shown
in Table 1. The mean baseline hemoglobin concentra-
tion was 13.8 ± 1.7 g/dl (range 8.1 - 18.7). Age was
negatively correlated with hemoglobin (r = -0.18, p <
0.01), and hemoglobin concentration was lower among
women (13.2 ± 1.6) than among men (14.2 ± 1.6 g/dl;
p < 0.01). Hemoglobin was not associated with stroke
type or stroke severity, but was lower among those with
prior disability, chronic kidney disease, cardiac disease
(congestive heart failure or atrial fibrillation or valvular
heard disease) and malignancy than those without.
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among both women and men.
Mortality data, the main outcome of interest, were
available for all patients. At 1-month after the event 728
patients (85%) were alive, and 586 (80%) of them had a
follow-up evaluation. At 1-year, 670 patients (78%) were
alive, and 501 (75%) of them had a phone follow-up
interview. The age, gender and stroke severity of
patients with available follow-up data at 1-months and
those with available data at 1-year were comparable to
the entire study cohort.
Anemia status and clinical outcome
Clinical outcomes by anemia status are presented in
Table 2. Patients with anemia exhibited poorer out-
comes at both 30-day and 1-year. Similar associations
were observed in men versus women, in younger versus
older patients, in patients with ischemic stroke versus
intracerebral hemorrhage, with no evidence for an inter-
action. Because of the imbalances in some baseline char-
acteristics, multivariable logistic regression was used to
evaluate the relationship between anemia status with
outcomes of interest after adjusting for potential con-
founders (Table 3). Patients with admission WHO-
defined anemia had an adjusted OR for all-cause death
after 1-month of 1.90 (95% CI, 1.05 to 3.43) and after 1-
year of 1.72 (95% CI, 1.00 to 2.93) and for the combined
end-point of disability, nursing facility care or death of
2.09 (95% CI, 1.13 to 3.84) and 1.83 (95% CI, 1.02 to
3.27) respectively. Adjusted HR for 1-year survival was
1.48 (95% CI, 1.04 to 2.10)
Entire range of hemoglobin concentrations and
clinical outcome
The relationships between gender-specific quartiles of
hemoglobin and outcomes of interest at 1-year are
depicted in Figure 1. Patients with hemoglobin in the
bottom quartile exhibited the highest rates of poor out-
come. Those in the middle quartiles exhibited the lowest
rates, while for patients with hemoglobin in the top
quartile, rates of all-cause death increased again. For the
combined end-point of disability, nursing facility care or
death, patients in the bottom gender-specific quartile
exhibited the highest rates while rates were lower across
the other quartiles.
Based on our study hypothesis and since the shape of
the relationship between hemoglobin and all-cause
death showed a quadratic relationship, logistic regres-
sion models were developed to estimate the linear and
quadratic relation between hemoglobin and outcomes of
interest (Table 4). Each unit increment in hemoglobin
squared was associated with increased adjusted odds of
Table 1 Baseline Characteristics of Study Cohort
N = 859
Age (mean ± SD) years 70.6 ± 12.5
range 29-100
Women 362(42.2%)
Type of event
Ischemic stroke 726 (84.6%)
Intracerebral hemorrhage 132 (15.4%)
Stroke severity (NIH stroke scale)
<5 426 (50.4%)
6 - 10 173 (20.5%)
>11 247 (29.2%)
Prior stroke 232 (27.0%)
Prior disability 265 (31.7%)
Hypertension 605 (70.5%)
Dyslipidemia 299 (34.9%)
Diabetes mellitus 281 (32.8%)
Chronic kidney disease 305 (38.0%)
Coronary heart disease (angina pectoris and/or
myocardial infarction)
268 (31.2%)
Other cardiac disease (congestive heart failure, atrial
fibrillation or valvular heart disease)
226 (26.3%)
Peripheral artery disease 71(8.3%)
Malignancy 78 (9.1%)
Continuous variables are expressed as mean ± SD. Categorical variables as
number (%)
Table 2 Clinical Outcomes by Anemia Status
Anemia status
End Point Yes
n = 163
No
n = 695
P-value
At 1-Month
All-cause death (%) 39 (23.9%) 92 (13.2%) <0.01
Disability, nursing facility or
death (%)
89 (65.9%) 262 (44.7%) <0.01
At 1-Year
All-cause death (%) 54 (33.1%) 135 (19.4%) <0.01
Disability, nursing facility
or death (%)
82 (66.1%) 225 (46.3%) <0.01
Table 3 Adjusted Odds-Ratios (95% Confidence Intervals)
for Outcomes of Interest by Anemia Status
Anemia status
End Point Yes No
At 1-Month
All-cause death (%) 1.90 (1.05 - 3.43) 1.0
Disability, nursing facility or death (%) 2.09 (1.13 - 3.84) 1.0
At 1-Year
All-cause death (%) 1.72 (1.00 - 2.93) 1.0
Disability, nursing facility or death (%) 1.83 (1.02 - 3.27) 1.0
Models were adjusted for age, gender, stroke type, stroke severity (NIH stroke
scale), prior disability, chronic kidney disease, other cardiac disease and
malignancy.
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0.03); after 1-year 1.09 (1.04 to 1.15; p < 0.01)], confirm-
ing that extremes of both low and high levels of hemo-
globin were associated with increased mortality.
Adjusted HR for 1-year survival was 1.05 (95% CI, 1.02
to 1.09, p < 0.01). As gender may influence the relation-
ship of hemoglobin to mortality, the model was repeated
testing for interaction of each hemoglobin term with
gender, but no interactions were identified. To visualize
the relation between hemoglobin and the probability to
all-cause death as demonstrated in the final logistic
regression model the Loess method was used. As
depicted in Figure 2, the curve reveals a non-linear asso-
ciation with increased rates at both extremes of hemo-
globin concentration.
Discussion
In this cohort of patients with acute stroke followed for
1-year, WHO-defined anemia was common in both men
and women, and a significant association was found
between anemia and risk forp o o ro u t c o m e .T h i sr e l a -
tionship did not differ between men and women or
between patients with intracerebral hemorrhage versus
ischemic stroke type. Moreover, the association between
admission hemoglobin and mortality was not linear; risk
for death increased at both extremes of hemoglobin.
Hemoglobin concentrations were inversely correlated
with age and were lower among those with prior disabil-
ity, chronic kidney disease, cardiac disease and malig-
nancy, yet the non-linear association with mortality
remained after adjusting for these potential confounders
as well as for stroke type and severity.
WHO-defined anemia was present in about a fifth of
patients in our cohort, and was a robust predictor of
mortality over 1-year. This finding corroborates a small
prior study of 250 ischemic stroke patients, observing
that anemia was a negative prognostic factor [17]. Ane-
mia is a particularly common condition among older
adults, with prevalence increasing with age. Anemia in
the elderly is associated with increased mortality, poorer
health-related quality of life, disability, and poorer physi-
cal performance [1-5]. Among patients with an acute
coronary syndrome, rates of anemia are similar to those
observed in our cohort [8,18], and anemia status is asso-
ciated with poor outcome [7,8,19,20].
High hemoglobin concentrations have been associated
with carotid atherosclerosis and may represent a risk
factor for ischemic stroke [21,22], but data on their
association with outcome after acute stroke are particu-
larly scarce and inconclusive. Sacco et al. found in the
population-based L’Aquila registry that high hematocrit
might represent an independent predictor of early
Figure 1 Outcome after 1-year by gender-specific quintiles of
admission hemoglobin. a. all-cause death rate; b. disability, nursing
facility care or death.
Table 4 Adjusted Odds-Ratios (95% Confidence Intervals)
for Outcomes of Interest by Hemoglobin Squared
End Point Hemoglobin × Hemoglobin P-value
At 1-Month
All-cause death 1.06 (1.005, 1.12) 0.03
Disability, nursing facility
or death
1.07 (1.001, 1.14) 0.05
At 1-Year
All-cause death 1.09 (1.04, 1.15) <0.01
Disability, nursing facility
or death
1.06 (0.998, 1.13) 0.06
Models were adjusted for age, gender, stroke type, stroke severity (NIH stroke
scale), prior disability, chronic kidney disease, other cardiac disease and
malignancy.
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men [23], In a group of patients with an acute ischemic
stroke studied with multimodal magnetic resonance
imaging, higher hematocrit had a significant indepen-
dent association with reduced reperfusion and greater
infarct size, suggesting that elevated levels may be a
potential physiologic determinant of reduced penumbral
salvage [24]. A pilot study on the association between
baseline hematocrit at the time of the ischemic stroke
and the discharge destination showed that midrange
concentrations were associated with a better discharge
outcome but were not related to mortality rate [25].
The increased mortality observed in our cohort of
stroke patients at both extremes of hemoglobin is in
agreement with prior observations in cardiac patients
and with some but not all reports among community
dwelling elderly [1,3]. It remains unclear whether the
impact of hemoglobin on mortality after stroke operates
through the same or different causal pathways at higher
vs. lower values. Anemia may induce hypoxia at the
most vulnerable regions when hemoglobin is reduced
below a critical level, while high hemoglobin, may
increase blood viscosity, affect cerebral blood flow and
is associated with pulmonary disease. Moreover, chroni-
cally high values might enhance cerebral atherogenesis
heading to a diseased and dysfunctional collateral bed
[21].
Potential limitations of this study should be consid-
ered. First, it is an observational study and therefore
causality cannot be inferred from the observed associa-
tions. The effects of unmeasured confounding variables
such as nutritional status, frailty, cognitive function or
complex interactions between covariates on the
observed association cannot be ruled out. Second, we
were unable to examine whether the relationship was
due to increased blood loss, impaired red blood cell
production, and/or increased red blood cell destruction
(in the case of low hemoglobin levels) or increased
red cell production (in the case of high hemoglobin
levels). Third, the use of blood transfusions was not
Figure 2 Loess curve (with 95% confidence intervals) of hemoglobin concentrations versus the estimated probability all-cause death
after 1-year.
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Admission hemoglobin concentrations were, however,
rarely in the range leading to blood transfusion in rou-
tine clinical practice. Finally, we did not measure ery-
thropoietin levels in these patients. In addition to
stimulating erythrocyte precursors, erythropoietin has
multiple neuroprotective effects [26,27], and thus, some
of our observations may be due to low or high levels of
erythropoietin or other intervening factors rather than
hemoglobin per se.
The influence of red blood-cell transfusion on clinical
outcomes in selected patients with acute stroke and low
hemoglobin has not been tested in trials nor discussed
in guidelines. The potential benefits of transfusion by
increasing oxygen-carrying capacity must be counterba-
lanced by risks of acute complications including infec-
tion, hemolytic reactions, volume overload, and further
activation of adverse biological or inflammatory pro-
cesses [28]. Achieving higher hemoglobin through phar-
macologic treatment with erythropoietin-stimulating
proteins was found to increase mortality, at least for
anemia due to chronic kidney disease [29]. Hemodilu-
tion therapy was not found to improve overall survival
or functional outcome in acute ischemic stroke, based
on a systematic review of the hemodilution trials [30].
Future areas of investigation should evaluate the causes
of increased mortality in individuals with low and high
hemoglobin concentrations, and to assess whether aim-
ing to a target range of hemoglobin concentrations may
improve long-term outcome after stroke.
Conclusions
We conclude that WHO-defined anemia is common in
both men and women among patients with acute stroke
and predicted poor outcome. Moreover, the association
between admission hemoglobin and mortality is not lin-
ear; risk for death increased at both extremes of hemo-
globin. Most importantly, our work suggests that
hemoglobin levels (both low and high) may need to be
considered as a potential factor in determining outcome
after stroke.
List of abbreviations
NIHSS: National Institutes of Health Stroke Scale; WHO: World Health
Organization.
Acknowledgements
This project was supported by the Israel National Institute for Health Policy
and Health Services Research.
Authors’ contributions
DT conceived the study, participated in its design and drafted the
manuscript. OM, RT, MT, and YS participated in data collection, interpretation
and reviewed the manuscript. NM performed the statistical analysis. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 26 September 2009 Accepted: 9 April 2010
Published: 9 April 2010
References
1. Zakai NA, Katz R, Hirsch C, Shlipak MG, Chaves PHM, Newman AB,
Cushman M: A prospective study of anemia status, hemoglobin
concentration, and mortality in an elderly cohort: The Cardiovascular
Health Study. Arch Intern Med 2005, 165:2214-2220.
2. Penninx BW, Pahor M, Woodman RC, Guralnik JM: Anemia in old age is
associated with increased mortality and hospitalization. J Gerontol A Biol
Sci Med Sci 2006, 61:474-9.
3. Culleton BF, Manns BJ, Zhang J, Tonelli M, Klarenbach S, Hemmelgarn BR:
Impact of anemia on hospitalization and mortality in older adults. Blood
2006, 107:3841-3846.
4. Dong X, de Leon CM, Artz A, Tang Y, Shah R, Evans D: A population-based
study of hemoglobin, race, and mortality in elderly persons. J Gerontol A
Biol Sci Med Sci 2008, 63:873-878.
5. Penninx BW, Pahor M, Cesari M, Corsi AM, Woodman RC, Bandinelli S,
Guralnik JM, Ferrucci L: Anemia is associated with disability and
decreased physical performance and muscle strength in the elderly.
J Am Geriatr Soc 2004, 52:719-24.
6. Nikolsky E, Aymong ED, Halkin A, Grines CL, Cox DA, Garcia E, Mehran R,
Tcheng JE, Griffin JJ, Guagliumi G, et al: Impact of anemia in patients with
acute myocardial infarction undergoing primary percutaneous coronary
intervention: analysis from the Controlled Abciximab and Device
Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial.
J Am Coll Cardiol 2004, 44:547-53.
7. Muzzarelli S, Pfisterer M: Anemia as independent predictor of major
events in elderly patients with chronic angina. Am Heart J 2006,
152:991-6.
8. Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, McCabe CH,
Gibson CM, Braunwald E: Association of hemoglobin levels with clinical
outcomes in acute coronary syndromes. Circulation 2005, 111:2042-9.
9. Go AS, Yang J, Ackerson LM, Lepper K, Robbins S, Massie BM, Shlipak MG:
Hemoglobin level, chronic kidney disease, and the risks of death and
hospitalization in adults with chronic heart failure: the Anemia in
Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR)
Study. Circulation 2006, 113:2713-23.
10. Shah RC, Wilson RS, Tang Y, Dong X, Murray A, Bennett DA: Relation of
hemoglobin to level of cognitive function in older persons.
Neuroepidemiology 2009, 32:40-6.
11. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J,
Holleran R, Eberle R, Hertzberg V, et al: Measurements of acute cerebral
infarction: a clinical examination scale. Stroke 1989, 20:864-70.
12. Adams HPJ, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL,
Marsh EEd: Classification of subtype of acute ischemic stroke. Definitions
for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute
Stroke Treatment. Stroke 1993, 24:35-41.
13. Brosius FC III, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM,
Moore MA, Pennathur S, Smith GL, Wilson PW: Detection of chronic
kidney disease in patients with or at increased risk of cardiovascular
disease: a science advisory from the American Heart Association Kidney
And Cardiovascular Disease Council; the Councils on High Blood
Pressure Research, Cardiovascular Disease in the Young, and
Epidemiology and Prevention; and the Quality of Care and Outcomes
Research Interdisciplinary Working Group: developed in collaboration
with the National Kidney Foundation. Circulation 2006, 114:1083-7.
14. Herndon R: Handbook of neurologic rating scales. New York: Demos
Vermande 1997.
15. Cleveland WS, Devlin SJ: Locally weighted regression: an approach to
regression analysis by local fitting. Journal of the American Statistical
Association 83:596-610, CR - Copyright © 1988, American Statistical
Association.
16. Hurvich CM, Simonoff JS, Tsai C-L: Smoothing parameter selection in
nonparametric regression using an improved Akaike anformation
criterion. Journal of the Royal Statistical Society. Series B (Statistical
Methodology) 1998, 60:271-293.
Tanne et al. BMC Neurology 2010, 10:22
http://www.biomedcentral.com/1471-2377/10/22
Page 6 of 717. Nybo M, Kristensen SR, Mickley H, Jensen JK: The influence of anaemia on
stroke prognosis and its relation to N-terminal pro-brain natriuretic
peptide. Eur J Neurol 2007, 14:477-82.
18. Alexander KP, Chen AY, Wang TY, Rao SV, Newby LK, LaPointe NM,
Ohman EM, Roe MT, Boden WE, Harrington RA, et al: Transfusion practice
and outcomes in non-ST-segment elevation acute coronary syndromes.
Am Heart J 2008, 155:1047-53.
19. Sarnak MJ, Tighiouart H, Manjunath G, MacLeod B, Griffith J, Salem D,
Levey AS: Anemia as a risk factor for cardiovascular disease in The
Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 2002,
40:27-33.
20. Vaglio J, Safley DM, Rahman M, Kosiborod M, Jones P, Thompson R,
Krumholz HM, Spertus JA: Relation of anemia at discharge to survival
after acute coronary syndromes. Am J Cardiol 2005, 96:496-9.
21. Irace C, Ciamei M, Crivaro A, Fiaschi E, Madia A, Cortese C, Gnasso A:
Hematocrit is associated with carotid atherosclerosis in men but not in
women. Coron Artery Dis 2003, 14:279-84.
22. Wannamethee G, Perry IJ, Shaper AG: Haematocrit, hypertension and risk
of stroke. J Intern Med 1994, 235:163-8.
23. Sacco S, Marini C, Olivieri L, Pistoia F, Carolei A: Contribution of hematocrit
to early mortality after ischemic stroke. Eur Neurol 2007, 58:233-8.
24. Allport LE, Parsons MW, Butcher KS, MacGregor L, Desmond PM, Tress BM,
Davis SM: Elevated hematocrit is associated with reduced reperfusion
and tissue survival in acute stroke. Neurology 2005, 65:1382-7.
25. Diamond PT, Gale SD, Evans BA: Relationship of initial hematocrit level to
discharge destination and resource utilization after ischemic stroke: a
pilot study. Arch Phys Med Rehabil 2003, 84:964-7.
26. Grasso G, Sfacteria A, Meli F, Passalacqua M, Fodale V, Buemi M,
Giambartino F, Iacopino DG, Tomasello F: The role of erythropoietin in
neuroprotection: therapeutic perspectives. Drug News Perspect 2007,
20:315-20.
27. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M: Treatment of stroke with
erythropoietin enhances neurogenesis and angiogenesis and improves
neurological function in rats. Stroke 2004, 35:1732-7.
28. Perrotta PL, Snyder EL: Non-infectious complications of transfusion
therapy. Blood Rev 2001, 15:69-83.
29. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D,
the CHOIR Investigators: Correction of anemia with epoetin alfa in
chronic kidney disease. N Engl J Med 2006, 355:2085-2098.
30. Asplund K: Haemodilution for acute ischaemic stroke. Cochrane Database
Syst Rev 2002, CD000103.
Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.
biomedcentral.com/1471-2377/10/22/prepub
doi:10.1186/1471-2377-10-22
Cite this article as: Tanne et al.: Anemia status, hemoglobin
concentration and outcome after acute stroke: a cohort study. BMC
Neurology 2010 10:22.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Tanne et al. BMC Neurology 2010, 10:22
http://www.biomedcentral.com/1471-2377/10/22
Page 7 of 7